Itch in psoriasis: epidemiology, clinical aspects and treatment options by Prignano, F et al.
© 2009 Prignano et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access arti-
cle which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical, Cosmetic and Investigational Dermatology 2009:2 9–13 9
ORIGINAL RESEARCH
Itch in psoriasis: epidemiology, clinical aspects 
and treatment options
F Prignano
F Ricceri
L Pescitelli
T Lotti
Department of Dermatological 
Sciences, University of Florence, 
Florence, Italy
Correspondence: Francesca Prignano
Department of Dermatological 
Sciences, University of Florence, 
Villa Basilewsky, via Lorenzo Il Magniﬁ  co 
n 104, 50129 Florence, Italy
Tel +55 626 4481
Email francesca.prignano@uniﬁ  .it
Background: Pruritus is an important symptom in psoriasis vulgaris, may be severe and 
seriously affect the quality of life of patients, but published data on its frequency and charac-
teristics are limited.
Objective: The study objective was to characterize the prevalence of itch in psoriatic patients 
and the effect of treatment modalities by using a comprehensive itch questionnaire of own 
design.
Methods: A structured itch questionnaire was given to 90 patients with moderate to severe 
chronic-plaque psoriasis selected consecutively from the patients visiting the Department of 
Dermatology of the University of Florence. The questionnaire concerned the areas involved 
psoriasis and pruritus, the pruritus characteristics, the worsening and relieving factors and treat-
ment modalities. Itch intensity was reﬂ  ected by a 10 point visual analog scale (VAS) and the 
degree of symptoms discriminated between mild (1–3), moderate (4–7) and severe (8–10).
Results: Almost 85% of psoriatic patients suffered from itching; the frequency of pruritus was 
daily and mean intensity by VAS scale was moderate. Presence and intensity of pruritus and body 
mass index (BMI) were correlated. 40% of patients with pruritus were overweight (BMI  25  30) 
and 10% obese (BMI  30). Almost all patients appeared unsatisﬁ  ed with the available treatment 
modalities for pruritus in psoriasis. Emollients, topical steroids and calcipotriol cream could 
relieve pruritus but their effect was temporary. Among the antipsoriatic therapies, phototherapy 
with narrow band ultraviolet B (nb-UVB) was the most effective treatment in reducing pruritus. 
Biological therapies, mainly etanercept and efalizumab, proved useful in its control.
Conclusions: The questionnaire was a useful tool to characterize itch, and the results might 
help us to better understand pruritus in psoriasis. The results conﬁ  rmed the need for a global 
study of psoriasis with regard to both the cutaneous manifestations and the itch symptom.
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Introduction
Itch (pruritus) is a common symptom of many dermatological and systemic diseases. 
Although very common, itch is very hard to describe. According to Bernhard: “itching 
is a sensation that, if sufﬁ  cently strong, will provoke either conscious or reﬂ  ex scratch-
ing or the desire to scratch”.1 It consists of multidimensional phenomena with sensory 
discriminative, cognitive, evaluative and motivational components. Itch has similarities 
with pain, but in contrast to pain itch induces scratch cycles, which combine elements 
of pleasure with pain.2
Severe itch can severely affect quality of life (eg, sleep deprivation) and can have 
serious psychological implications (including temptation to suicide). Mild to severe 
pruritus is a common symptom in numerous inﬂ  ammatory skin disorders, including 
atopic dermatitis, eczema or lichen planus. Pruritus is an important symptom also in 
psoriasis vulgaris, but published data on both its prevalence and characteristics are 
limited. Its prevalence in different parts of the world ranges fromm 64% to 84%.3,4 Clinical, Cosmetic and Investigational Dermatology 2009:2 10
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According to Reich et al pruritus intensity in psoriatic 
patients is signiﬁ  cantly correlated with quality of life impair-
ment, level of stigmatization and severity of depressive 
symptoms.5
The objective of our study was to characterize the 
prevalence of the itch in psoriatic patients and the effect of 
treatment modalities by using a comprehensive itch ques-
tionnaire.
Methods
This study was conducted between October 2007 and March 
2008 in the Department of Dermatology of the University 
of Florence.
A structured itch questionnaire of our own design 
(Table 1) was given to 90 patients with moderate to severe 
chronic-plaque psoriasis. Patients were selected consecu-
tively from those visiting the Department in this period. All 
patients who had other dermatological or general illnesses 
(such as renal or hepatic diseases) causing pruritus were 
excluded from the study.
The 90 study patients (45 females and 45 males; age range 
21–84 years) were divided into 3 groups according to the 
treatment. Thirty patients were on narrow-band ultraviolet B 
(nb-UVB) treatment, 30 on topical or systemic traditional 
treatments, and 30 underwent biological treatment with 
anti-tumor necrosis factor-α (anti-TNF-α) or anti-CD11a 
monoclonal antibody.
Average disease duration was 1 to 65 years. Signs and 
symptoms of psoriatic arthritis were shown by 15% of 
patients.
After a brief explanation of the research project, patients 
were invited to ﬁ  ll in a questionnaire on pruritus and psoriasis; 
the questionnaire took approximately 10 minutes to complete. 
No patients refused to respond to the questionnaire.
The questionnaire asked about age, sex, height and 
weight, job category, and marital status. It concerned 
the areas affected by psoriasis and pruritus, pruritus 
characteristics, worsening and relieving factors, and 
treatment modalities. A visual analog scale (VAS) of 0 to 
10 was used to score pruritus as mild (1–3), moderate (4–7) 
and severe (8–10).
Statistical analyses were done using the SPSS program. 
Simple descriptions and frequencies of various factors 
were tabulated. Associations between factors were determined 
Table 1 Questionnaire
Demographic variables
Age
Sex
Height and weight
Marital status
Education
Clinical variables
Age at diagnosis
Type of psoriasis °Vulgaris °Pustulous °Erytrodermic °Artropatic
PASI
Previous treatments °Topical °Systemic (CsA, MTX, Retinoids, PUVA, nb-UVB)
Stress factors
Pruritus variables
Presence of pruritus °Yes       °No
Sites of pruritus
Intensity of pruritus (VAS) °Mild (1–3)   °Moderate (4–7)   °Severe (8–10)
Frequency of pruritus °Seldom     °Often     °Always
During the night °Yes       °No
Signs of scratching °Yes       °No
Modalities and efﬁ  cacy of treatments
Antipruritus therapies
Antipsoriatic therapies
Abbreviations: PASI, Psoriasis Area and Severity Index; VAS, visual analog scale;  CsA, cyclosporin-A;  MTX, methotrexate;  PUVA, psoralen + ultraviolet-A; nb-UVB, narrow-band 
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using a chi-square test with odds ratio (OR) with 95% con-
ﬁ  dence interval (95% CI) whenever appropriate. Pearson’s 
correlation test was used to show the correlation of different 
variables with pruritus intensity. P  0.05 was considered 
signiﬁ  cant.
Results
In our survey 83% of psoriatic patients suffered from itching 
(Table 2B). In 45% of these patients pruritus appeared daily 
(in 32% “often” and in 13% “always”) (Table 2D).
Most patients described pruritus as a sensation of stinging 
(20%) and burning (15%); the intensity reﬂ  ected by VAS 
scale was scored as mild only in 13%, moderate in 37% 
and severe in 33% of patients. Seventy-ﬁ  ve percent of itch 
patients had to scratch until bleeding (Table 2C). Itch was 
most frequent at night, and 50% of patients reported difﬁ  culty 
in falling asleep.
Pruritus presence and severity was not correlated 
signiﬁ  cantly with patient age, sex, marital status, alcohol 
and smoking habits, and duration and severity of psoriasis 
according to Psoriasis Area and Severity Index scores 
(PASI).6 Pruritus intensity and body mass index (BMI) were 
correlated: 40% of patients with pruritus were overweight 
(BMI  25  30) and 10% obese (BMI  30) (Table 2E). 
Pruritus intensity in these patients was moderate to severe 
(VAS  7).
Patients reported regional variations in the sites of 
pruritus; the most affected anatomical sites were the scalp 
(50%), the lower legs and the back. Some patients reported 
also a correlation between pruritus and presentation of 
psoriatic plaques. Itching was otherwise limited to psoriatic 
lesions (70% of cases), whereas in 30% it involved also 
non-lesional skin.
Stress was identiﬁ  ed as an aggravating factor of pruritus by 
67% of the patients. All patients who experienced severe punc-
tual stress before psoriasis onset and exacerbations suffered 
from pruritus, signiﬁ  cantly different compared with subjects 
in which psoriasis was apparently non-stress-related.7
The factors found to reduce itch intensity differed among 
patients: behavior (such as sunbathing and cold showers), 
special diets (without nuts, strawberries, red wine, chocolate, 
blue cheese, milk and sweet products), and speciﬁ  c antipru-
ritic and antipsoriatic treatments.
Among the pruritus treatment modalities, topical 
therapies such as moisturizers and steroid creams were effec-
tive in 24% and 17% of patients, respectively, for control of 
itch in the acute phase but they showed limited long-term 
effects. Third-generation antihistamines helped for a few 
days in 13% of cases. Thirty-six percent of patients did not 
use any treatment or could not ﬁ  nd any effective treatment.
Among the specific antipsoriatic therapies, nb-UVB 
(311 nm; 2–J/cm2) was shown to be of beneﬁ  t after a 2 weeks 
treatment (2 or 3 times a week) in 15% of cases. Biological 
therapies with a standard dosage of both anti-TNF-α and 
anti-CD11a relieved pruritus symptoms in the same percent-
age of patients (Table 2F). In most cases (45%) no treatment 
relieved itching.
Conclusions
All patients enjoyed ﬁ  lling in the questionnaire with the help 
of a medical doctor, and welcomed the opportunity to talk 
about their symptoms.
We found a high pruritus prevalence in chronic-plaque 
type psoriasis vulgaris (85% of patients). Despite a high 
frequency of this symptom, the pathogenesis of pruritus in 
psoriasis remains unclear. Cutaneous innervation is high 
in psoriatic skin with pruritus compared with non-pruritic 
skin. Sprouting of nerves could accelerate the intensity of 
itching in inﬂ  amed skin of psoriasis patients,8 which could be 
the reason why patients felt more pruritus when the phases 
of the disease were more active.
Almost all patients agreed that stress is an important 
enhancing factor for psoriasis and also for pruritus in psoriasis. 
The patients who did not remember a stress event before the 
disease onset did not have pruritus.9 The mechanism by which 
stress provokes pruritus in psoriasis is not understood yet; 
psychological stress causes alterations in levels of certain neu-
ropeptides, such as substance P, either in the central nervous 
system or in tissues. Various mediators as neuropeptides, 
in addition to histamine released from unmyelinated nerve 
endings, might have a role.10 It is also known that an increase 
in substance P potentiates mast cell degranulation in stress 
condition. Interaction between nerve, neuropeptides and mast 
cells leads to pruritic inﬂ  ammation.11
Overweight or obese patients experienced more intense 
pruritus, which could explain the tendency for anatomical 
folds (some of our psoriatic patients have also previously 
had inverse psoriasis) to rub together. Moreover, sweating 
and body temperature increase in obese persons, which 
worsens pruritus.
Some patients tried to relieve pruritus by taking cold 
showers. Sensation can be inhibited by substituting the 
temperature of skin with another sensation to interfere with 
the steps in the evolution of scratching. Such a substitution 
may be achieved by cooling the skin by using cold 
compresses, ice cubes and so forth.Clinical, Cosmetic and Investigational Dermatology 2009:2 12
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Currently available drugs to relieve pruritus are not 
effective and almost all patients were unsatisﬁ  ed with the 
available treatment modalities. Various emollients, topical 
steroids and calcipotriol cream could relieve the pruritus but 
their effect is temporary.12
It is generally accepted that the histamine blockade does 
not prevent pruritus in psoriasis:13 less than 15% of psoriatic 
patients claimed that oral antihistamines were effective in 
reducing pruritus.
The ineffective action of antihistamines for pruritus in 
psoriasis might be explained by the fact that various pruritic 
mediators, separately or combined with histamine, play a 
role in the mechanism of pruritus in psoriasis vulgaris.9,14 
Pruritus intensity and histamine plasma level in psoriasis 
were not correlated, and no difference was observed in 
histamine plasma levels between pruritic and nonpruritic 
patients with psoriasis.15
Among the antipsoriatic therapies, phototherapy was the 
most effective treatment effective in reducing pruritus (15% 
of patients on UVB treatment); phototherapy down-regulates 
substance P-positive nerve ﬁ  bers, reducing pruritus not only 
in psoriasis, but also in other inﬂ  ammatory skin disease.16
Both biological therapies, etanercept and efalizumab, 
were useful in relieving pruritus, in contrast to published 
data. However, we were not able to establish which of the 
biologics is more effective, because the number of patients 
was insufﬁ  cient to demonstrate statistical signiﬁ  cance.
The questionnaire was a useful tool for characterizing itch, and 
the results might help us to better understand pruritus in psoriasis. 
The results conﬁ  rmed the need for a global study of psoriasis with 
regard to both cutaneous manifestations and the itch symptom.
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